

Requirements for distribution of ZAVZPRET In-Person Speaker Program Invitation – Print
(PP-ZAZ-USA-1001)

Purpose

This document provides Reps with guidance that must be used when distributing print invitations to an HCP

Directions for Use

- A full copy of the Prescribing Information **must** accompany each print invitation that is distributed
- When stapling the PI to the document, be certain to NOT obscure other text on the piece, such as the ISI
- This invitation **must** be printed in color
- Be certain to print ALL the pages of this piece
- Take care when filling in the variable text and be sure to only fill in the specified content; do not include any other text

THIS PAGE IS FOR INTERNAL USE ONLY

You are invited to attend a ZAVZPRET® (zavegepant)
LIVE SPEAKER PROGRAM

Migraine Management: An Approach for Individualized Care Using an Intranasal CGRP Receptor Antagonist

Join us to learn more about available treatments for your adult patients with migraine.

 **Presented By**
ROGER CHAPMAN, NP

 **Date and Time**
Tuesday, September 8, 2026
6:00 PM Central Time

 **Location**
Prime 102
102 North College Avenue
Tyler, Texas 75702
(903) 400-9102

Continuing medical education (CME) credits are not available for this program.
Speaker is paid by Pfizer Inc.

REGISTER NOW! 

Please RSVP for this event by contacting:

Brandi Dunford: , brandi.dunford@pfizer.com

Kindly provide your full name, degree, specialty, address including state, and email address when registering, so you can be confirmed.
Please also provide this Meeting ID# **INT-0096666** when you RSVP.

Because late arrivals may be prohibited from participating in the program, please make every effort to arrive by the designated start time.
You are expected to remain for the duration of the program.

CGRP, calcitonin gene-related peptide.

INDICATION for ZAVZPRET

ZAVZPRET (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION for ZAVZPRET

Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, facial swelling, and urticaria, have occurred in patients treated with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Please see accompanying full Prescribing Information.
Please see additional Important Safety Information for ZAVZPRET on next page.

Zavzpret®
(zavegepant) nasal spray
10 mg 



IMPORTANT SAFETY INFORMATION for ZAVZPRET (CONT'D)

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists.

If signs or symptoms of Raynaud's phenomenon develop, discontinue ZAVZPRET. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

Adverse Reactions: Most common adverse reactions (occurring in $\geq 2\%$ of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs $<1\%$).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: *Pregnancy:* It is not known if ZAVZPRET can harm an unborn baby. *Lactation:* It is not known whether ZAVZPRET passes into breast milk. *Hepatic Impairment:* Avoid use in patients with severe hepatic impairment.

Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CL_{cr}) less than 30 mL/min.

Please see accompanying full Prescribing Information.

Notice: Pfizer is committed to the appropriate marketing of its products to ensure that interactions with HCPs are professional exchanges designed to benefit patients and enhance the practice of medicine. All Pfizer-sponsored programs are conducted in accordance with PhRMA Code principles to address a bona fide educational need with appropriate attendees in a venue and manner conducive to informational exchange.

State and Federal Employees: State and federal laws and regulations may carry additional restrictions. By attending this event, you confirm that you have obtained any necessary approvals from your employer.

Public Disclosures: Pfizer reports payment and transfer of value data as required by federal and state transparency laws.

State Law Restrictions:

Minnesota: Regardless of where you practice or reside, if you are a Minnesota-licensed practitioner with prescribing privileges, then you may not consume any food or beverage associated with this event.

Vermont: Regardless of where you practice or reside, if you are a Vermont-licensed HCP, you may not consume any food or beverage associated with this event. Additionally, if you are an employee/agent of a Vermont HCP (e.g., PAs, non-prescribing nurses, etc.), regardless of where you practice or reside, you may not consume any food or beverage associated with this event.

Pfizer does not provide or pay for alcohol in connection with any Pfizer-sponsored program.

HCP, healthcare provider; PA, physician assistant.

This promotional program is for US healthcare professionals only.

© 2026 Pfizer Inc. All rights reserved. March 2026 PP-ZAZ-USA-1001

